A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease

The goal of this clinical trial is to learn if study drug Fosamprenavir-Sodium Alginate (FOS-SA) administered orally improves symptoms for Proton Pump Inhibitor (PPI)-refractory Gastro Esophageal Reflux Disease (GERD).
The main questions it aims to answer are:
1. Does FOS-SA significantly improve heartburn severity over the 8-week treatment period
2. Does FOS-SA significantly improve regurgitation frequency over the 8-week treatment period
3. Does FOS-SA significantly improve symptoms of persistent GERD over the 8-week treatment period
Researchers will compare FOS-SA to a placebo (a look-alike substance that contains no active drug) to see if FOS-SA works to treat PPI-refractory GERD.
Participants will:
1. Take FOS-SA or placebo every day BID (twice a day) for 8 weeks
2. Visit the Adult Translational Research Unit (ATRU) seven times for consenting, screening, and checkups and tests
3. Keep a daily diary of their symptoms of persistent GERD

Start Date01 May 2025

Sponsor / Collaborator

Medical College of Wisconsin

NCT04383262 / Not yet recruitingPhase 2IIT

A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir-Sodium Alginate Suspension for Laryngopharyngeal Reflux

Laryngopharyngeal reflux (LPR) causes chronic cough, throat clearing, hoarseness, and dysphagia and if left untreated can promote the development of laryngeal cancer. More than 20% of the United Stated population suffer from LPR, yet there is no effective medical therapy. Proton pump inhibitors (PPIs), which inhibit gastric acid production but do not prevent reflux events, continue to be prescribed for LPR despite their poor efficacy for this patient population, high cost ($26 billion/year), and associated risks. Pepsin, detected in the airway of these patients and now known to cause laryngeal inflammation and promote disease independent of gastric acid, is a key therapeutic target. We report preclinical studies of select HIV inhibitors that bind to and inhibit pepsin and thus hold promise for the treatment of LPR. In support, a very low incidence of LPR was found in patients taking these drugs compared to the general population. HIV inhibitors are ideal drugs to repurpose because they target a foreign virus. Thus, a repurposing approach can be used to safely perform proof of concept testing of the efficacy of a pepsin inhibitor for LPR. The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir-sodium alginate(FOS-SA) for LPR. FOS-SA will be used at the FDA approved, manufacturers recommended dose for HIV for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR and combined multi-channel intraluminal impedance - pH (MII-pH) confirmed laryngeal reflux events. Routine clinical outcome measures for LPR (Reflux Symptom Index, Reflux Finding Score, Voice Handicap Index) will be documented pre- and post-treatment with Oral Fosamprenavir-Sodium Alginate for LPR(n = 52) and placebo (n = 52). Additional research measures will include repeat administration of a newly created Daily Symptom Reflex Diary, as well as an intermittently distributed Patient Global Impression - Static & Change scales. Saliva will be collected pre-treatment for both pepsin protein analysis and kinetic activity assay to compare with clinical measures. There is currently no effective medical therapy for LPR and pepsin is the key therapeutic target. Identification of an FDA approved drug which inhibits pepsin allows for a clinical trial to determine efficacy using a faster and safer repurposing approach to address a significant gap.

Start Date01 Nov 2024

Sponsor / Collaborator

Medical College of Wisconsin

CTRI/2020/02/023247 / CompletedNot Applicable

A single centre, site randomized, double-blind, comparative study to evaluate the impact of topical application of FOS and GOS on skin hydration, barrier function, and microbiome regulation in human adult subjects with dry, flaky skin, otherwise healthy.

Start Date14 Feb 2020

Sponsor / Collaborator

Tata Chemicals Ltd.

100 Clinical Results associated with Fosamprenavir calcium

100 Translational Medicine associated with Fosamprenavir calcium

100 Patents (Medical) associated with Fosamprenavir calcium

611

Literatures (Medical) associated with Fosamprenavir calcium

09 Dec 2024·INORGANIC CHEMISTRY

Diffuse Ferroelectric Phase Transition-Dependent Photovoltaic Effect in BiFeO₃–BaTiO₃-Based Solid Solutions

Article

Author: Yang, Jie ; Sun, Yu-Ping ; Zhao, Gao-Chao ; Song, Wen-Hai ; Yin, Li-Hua ; Xie, Lei ; Tong, Peng ; Dou, Jin-Quan ; Zhang, Ran-Ran

The photovoltaic effect in ferroelectric (FE) semiconductors, i.e., the FPV effect, is attracting increasing attention. However, the microscopic mechanism of the FPV effect is still largely unknown. Here, we investigated the effects of crystal structure, dielectric, FE, and domain features on the FPV effect in the 0.7BiFe_1-xCr_xO₃-0.3BaTi_1-xMn_xO₃ (BFC-BTM) (0.01 ≤ x ≤ 0.07) system. We observed a coexisting rhombohedral and tetragonal to pseudocubic phase transition for x ≥ 0.05. This structural transition was accompanied by a significant reduction in the lattice distortion and disappearance of macro-sized FE domains. We found a substantial increase and decrease in the degree of the diffuseness of the relaxor FE phase transition and the open-circuit photovoltage V_OC, respectively, for x ≥ 0.05, in contrast to the relatively weak variation in the remnant polarization. Our results demonstrate that the FPV effect depends weakly on FE polarization but strongly on the complex submicron domain-related diffused relaxor FE phase transition and crystal structure in BFC-BTM. These results were discussed based on the non-centrosymmetry-related shift current mechanism.

02 Dec 2024·AMERICAN JOURNAL OF EPIDEMIOLOGY

Neighborhood-level fatal police violence and severe maternal morbidity in California

Article

Author: Ahern, Jennifer ; Riddell, Corinne A ; Mujahid, Mahasin S ; Hailu, Elleni M ; Bradshaw, Patrick T ; Carmichael, Suzan L ; Tucker, Curisa

Abstract:

Police violence is a pervasive issue that may have adverse implications for severe maternal morbidity (SMM). We assessed how the occurrence of fatal police violence (FPV) in one’s neighborhood before or during pregnancy may influence SMM risk. Hospital discharge records from California between 2002 and 2018 were linked with the Fatal Encounters database (n = 2 608 682). We identified 2184 neighborhoods (census tracts) with at least 1 FPV incident during the study period and used neighborhood fixed-effects models adjusting for individual sociodemographic characteristics to estimate odds of SMM associated with experiencing FPV in one’s neighborhood anytime within the 24 months before childbirth. We did not find conclusive evidence on the link between FPV occurrence before delivery and SMM. However, estimates show that birthing people residing in neighborhoods where 1 or more FPV events had occurred within the preceding 24 months of giving birth may have mildly elevated odds of SMM than those residing in the same neighborhoods with no FPV occurrence during the 24 months preceding childbirth (odds ratio [OR] = 1.02; 95% confidence interval [CI], 0.99-1.05), particularly among those living in neighborhoods with fewer FPV incidents (1-2) throughout the study period (OR = 1.03; 95% CI, 1.00-1.06). Our findings provide evidence for the need to continue to examine the population health consequences of police violence.

01 Dec 2024·COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES

Molecular typing of Protoparvovirus carnivoran 1 in Egyptian cats diagnosed with feline panleukopenia

Article

Author: El-Sayed M, Samah ; Safwat, Mahmoud S ; Mansour, Othman N O ; Safwat, Mahmoud S. ; Saeed, Omar S ; Farouk, Manar M. ; Farouk, Manar M ; Saeed, Omar S. ; Hassan, Ayah M ; Samah El-Sayed, M. ; El-Sayed M., Samah ; Mansour, Othman N.O. ; Ali, Mohamed E ; Ali, Mohamed E. ; Amer, Haitham M ; Hassan, Ayah M. ; Amer, Haitham M.

Feline panleukopenia (FPL) in cats is caused by either feline parvovirus (FPV) or canine parvovirus (CPV-2), which belong to the same species "Protoparvovirus carnivoran 1". While FPV is widely recognized as the principal cause of FPL, CPV-2 has been detected at a higher rate than FPV in sick cats in a recent Egyptian study. To assess this conflict, the present study aimed to determine which Protoparvovirus carnivoran 1 is commonly associated with FPL in Egyptian cats. From Dec-2022 to Jan-2024, 43 cats presenting with acute gastroenteritis and testing positive for FPL using in-clinic assay, SNAP® parvo, were tested for Protoparvovirus carnivoran 1 DNA using conventional PCR. Typing of Protoparvovirus carnivoran 1 was conducted by partial VP2 gene sequencing. Additional epidemiological aspects of the disease were investigated, including seasonal pattern, case-fatality rate, median survival time to death, and the association between FPL outcomes and selected factors like age, sex, vaccination status, and clinical signs (vomiting and diarrhea). All cats tested positive for Protoparvovirus carnivoran 1 DNA and FPV was detected in all cats with strong PCR amplicons (n=39). The following seasonal pattern was recorded: cases emerging in autumn, peaking during winter, declining in spring, and disappearing in summer. The case-fatality rate was 41.6 %, and the median time to death was two days. None of the studied factors affected FPL outcomes. In conclusion, FPL in Egyptian cat populations is primarily caused by FPV, not CPV-2, and is particularly prevalent in winter.

News (Medical) associated with Fosamprenavir calcium

29 Jan 2024

·www.biospace.com

Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections

Produced in the U.S., the generic anti-fungal drug is fully substitutable for Noxafil® LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi announced today it has introduced Posaconazole Injection, a generic substitute for Noxafil®, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules. This press release features multimedia. View the full release here: Fresenius Kabi Posaconazole Injection, a generic substitute for Noxafil® (Photo: Business Wire) Available in a 300 mg per 16.7 mL vial, Posaconazole Injection is used to treat invasive aspergillosis, a serious fungal infection, in adults and teenagers 13 years of age and older. It is also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older. “The introduction of Posaconazole Injection reflects Fresenius Kabi’s ongoing commitment to expanding our portfolio of affordable generic options for the treatment and/or prevention of life-threatening infections,” said John Ducker, president and CEO of Fresenius Kabi USA. Posaconazole Injection is produced at the company’s pharmaceutical production site in Grand Island, New York. Fresenius Kabi has invested nearly $1 billion to expand and update its U.S. pharmaceutical production and distribution network. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List. “We are doubling our U.S. manufacturing capacity to enhance the resilience of our supply chain, which helps assure fast, reliable service for our customers and the patients they serve,” said Lindsey Thomas, senior vice president of marketing of Fresenius Kabi USA. “Our investments will help patients gain access to the treatments they need – when and where they need them most.” Learn more about Fresenius Kabi’s commitment to strengthening its domestic supply chain at MoreInAmerica.com. About Fresenius Kabi Fresenius Kabi ( ) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn. References *Noxafil® is a registered trademark of Merck Sharp & Dohme LLC. About Posaconazole Injection Posaconazole is an azole antifungal indicated as follows: Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: Posaconazole injection: adults and pediatric patients 2 years of age and older. IMPORTANT SAFETY INFORMATION Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. Coadministration of Posaconazole with the following drugs is contraindicated; Posaconazole increases concentrations and toxicities of: Sirolimus CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 Ergot alkaloids Venetoclax: in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp of phase Calcineurin-Inhibitor Toxicity: Posaconazole increases concentrations of cyclosporine or tacrolimus; reduce dose of cyclosporine and tacrolimus and monitor concentrations frequently. Arrhythmias and QTc Prolongation: Posaconazole has been shown to prolong the QTc interval and cause cases of TdP. Administer with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs known to prolong QTc interval and metabolized through CYP3A4. Electrolyte Disturbances: Monitor and correct, especially those involving potassium (K+), magnesium (Mg++), and calcium (Ca++), before and during Posaconazole therapy. Hepatic Toxicity: Elevations in liver tests may occur. Discontinuation should be considered in patients who develop abnormal liver tests or monitor liver tests during treatment. Renal Impairment: Posaconazole injection should be avoided in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Posaconazole injection. Concomitant Use with Midazolam: Posaconazole can prolong hypnotic/sedative effects. Monitor patients and benzodiazepine receptor antagonists should be available. Vincristine Toxicity: Concomitant administration of azole antifungals, including Posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including Posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. Venetoclax Toxicity: Concomitant administration of Posaconazole with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome, neutropenia, and serious infections; monitor for toxicity and reduce venetoclax dose. Adult Patients: Common adverse reactions in studies with Posaconazole in adults are diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia. Pediatric Patients: Common adverse reactions (incidence >20%) receiving 6 mg/kg Posaconazole injection in a study in pediatric patients are pyrexia, febrile neutropenia, vomiting, mucosal inflammation, pruritus, hypertension, hypokalemia, and stomatitis. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or . Drug Interactions: Interaction Drug Interaction Rifabutin, phenytoin, efavirenz Avoid coadministration unless the benefit outweighs the risks Other drugs metabolized by CYP3A4 Consider dosage adjustment and monitor for adverse effects and toxicity Digoxin Monitor digoxin plasma concentrations Fosamprenavir Monitor for breakthrough fungal infections Pregnancy: Based on animal data, may cause fetal harm. Pediatrics: Safety and effectiveness in patients younger than 2 years of age have not been established. Severe Renal Impairment: Monitor closely for breakthrough fungal infections. This Important Safety Information does not include all the information needed to use Posaconazole Injection safely and effectively. Please see the full prescribing information for Posaconazole Injection available at .

Drug Approval

28 Nov 2022

·www.biospace.com

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

-- Company’s platform aims to create programmable, long-acting mRNA therapies that offer curative treatments for cancer and beyond -- -- Series A1 round led by new investor FPV Ventures -- BOSTON--(BUSINESS WIRE)-- Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million. New investor FPV led the round, with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate. This press release features multimedia. View the full release here: Strand Therapeutics co-founders Jake Becraft, Ph.D., CEO and Tasuku Kitada, Ph.D., President, Head of R&D. (Photo credit: Doug Levy) The funding will be used to advance Strand’s first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year. The funds will also be used to further develop its systemic delivery mechanism, which is designed to deliver tumor microenvironment-modifying mRNA to tumor sites and immune cells. To support these efforts, Strand will expand its multidisciplinary team across biology, bioengineering, bioinformatics, manufacturing, automation, and various G&A functions. Strand’s mission is to improve the efficacy, safety, ease of delivery and cost-effectiveness of treatments for deadly and chronic illnesses, through the use of long-acting programmable mRNA-based therapeutics that can deliver multi-functional treatments. mRNA therapeutics sense biomarkers found in cancer cells and express proteins only inside cancer cells. Strand is developing a pipeline of programmable, long-acting mRNA therapeutics that will be delivered in nanoparticles. The result is the ability to precisely control the location, timing, and expression level of mRNA within the patient, which is expected to have a better safety profile. “We raised this round at a step-up valuation from several of the most reputable global investors in the industry,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics. “The idea behind Strand and programmable mRNA in cancer, is to stimulate an immune response against the tumor using messenger RNA. With support from a world-class investor consortium, we are set to accelerate clinical development for our lead candidate in oncology with first-in-human data expected shortly following trial initiation. Our technology will enable mRNA to reach its full potential and expand beyond the scope of vaccines into a rigorous therapeutic modality.” “Strand is bringing the promise and potential of messenger RNA-based therapeutics beyond vaccines to treat some of the hardest diseases to target such as cancer,” said Pegah Ebrahimi, Co-Founder & Managing Partner of FPV. “mRNA is a future cornerstone of medicine, and Strand is on an ambitious path to push the industry beyond the challenges of traditional mRNA technologies with their precision. The convergence of biology and technology with next-generation programmable mRNA will fuel new opportunities for this ground-breaking technology to improve human lives, beginning with the millions of patients with cancer who desperately need new therapies with better efficacy and safety. We could not be more thrilled to back this remarkable team.” “The COVID-19 vaccines introduced the world to the astounding promise of mRNA therapeutics. While these vaccines literally saved the world, they represent “mRNA 1.0” which suffers from poor expression and nonspecific targeting of diseased tissues which have severely limited the scope of use,” said Jory Bell, General Partner at Playground. “Over a decade ago, scientists at MIT began developing a synthetic biology solution to enable truly programmable drugs with the ability to target diseased tissues while avoiding healthy tissues. Those scientists eventually founded Strand Therapeutics to realize the full potential of “mRNA 2.0” and we are thrilled to continue to support Strand in its mission to bring precision mRNA therapies to patients.” Strand genetically programs logic circuits that control the location, timing, and intensity of expression of therapeutic proteins within the patient’s body, to enable the precise and controlled delivery of multiple disease treatments in an RNA-modality agnostic manner. Such genetic programming enables Strand’s mRNA to sense and implement cell-type specific expression by sensing and classifying the unique microRNA expression signatures of cells. The company signed a partnership deal with BeiGene to develop and commercialize multi-functional mRNA treatments for solid tumors. About Strand Therapeutics Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Strand’s mission is to develop improved treatment options for cancer and other life-threatening diseases. The company is headquartered in Boston, MA. For more information, visit . Follow us on Twitter @StrandTx. About FPV FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by industry veterans Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO and CIO at Morgan Stanley and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio.

VaccinemRNAsiRNA

13 Jul 2022

·www.biospace.com

Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million

-- Proceeds will enable Xilis to build its capabilities in supporting biopharma collaborations for drug discovery -- -- Extension led by new investor FPV Ventures – DURHAM, N.C.--(BUSINESS WIRE)-- Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million. New investor FPV Ventures led the extension, with participation from fellow new investor Alexandria Venture Investments and existing investors EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV (formerly Google Ventures), the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures, Alix Ventures and other strategic partners. “Despite unprecedented market conditions in the biotech sector, we raised this extension at a step-up valuation and from several of the most reputable global investors. Our investors are strongly encouraged by the progress we have made in building diagnostic programs that predict patient response and achieving significant traction in partnered drug discovery and development,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.” The company will use the Series A funding to advance its proprietary MOS platform. This innovative MOS technology is the first truly scalable patient-derived model that recapitulates the tumor microenvironment and immune interactions necessary for next-generation immuno-oncology and cell therapy drug discovery. In addition, the MOS platform can be applied in a clinical setting to aid clinicians to make precision oncology treatment decisions, identifying treatments that lead to the best response for each patient. “Xilis has pushed forward and achieved meaningful scientific breakthroughs that will change the way cancer drugs are being discovered and how patients are being selected to achieve the most optimal response – realizing the goal of personalized precision oncology,” said Wesley Chan, Co-Founder & Managing Partner of FPV Ventures. “With support from a world-class investor consortium, Xilis is set to continue its efforts in clinical diagnostics and accelerate the company’s growth by expanding its MOS technology into biopharma R&D and drug development.” Recently, the company announced its participation in the Netherlands-based Oncode-PACT Consortium to accelerate the development of cancer drugs and was selected as the cover article/story in the June issue of the journal Cell Stem Cell highlighting its MOS technology and application in precision oncology. “Over the last year, Xilis has made tremendous progress in advancing their MOS platform, demonstrating its value both for physicians and biopharma partners, while addressing the significant challenges faced with precision and predictability in cancer treatments,” said Ayman AlAbdallah, Partner, Mubadala Capital. “As Mubadala continues to support companies across their entire life cycle, we are excited to back Xilis once again in their work toward impacting the future of healthcare.” About Xilis Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up the discovery and clinical development of new drug candidates. To learn more about Xilis, visit our website at Xilis.com or follow us on LinkedIn. About FPV FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO of Morgan Stanley Tech Banking and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio. About Mubadala Capital Mubadala Capital is the wholly owned asset management arm of Mubadala Investment Company. Since its inception a decade ago, Mubadala Capital has grown to become a global asset manager of significant scale, with over US $16 billion of assets under management and a presence in London, New York, San Francisco, Rio de Janeiro, and headquarters in Abu Dhabi. Through its four businesses, Mubadala Capital manages over US $10 billion in third-party capital vehicles on behalf of its institutional investors, including three private equity funds, two early stage venture funds, a public equities fund, and two funds in Brazil focused on special situations.

Cell TherapyCollaborate

100 Deals associated with Fosamprenavir calcium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fosamprenavir calcium	J05AE07	DB01319

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	US	ViiV Healthcare Co.	20 Oct 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpesviridae Infections	Phase 1	US	ViiV Healthcare Ltd.	01 Sep 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00802074 (CTgov)	Not Applicable	-	45	Fosamprenavir+Raltegravir (Group A)	ulesdrzkdi(jhkeujnojl) = ltegrrywfb awhngmkbsu (xowtcisydq, rhopwampab - wbkzriehcq) View more	-	29 Jan 2016
				Fosamprenavir+Raltegravir (Group B)	ulesdrzkdi(jhkeujnojl) = smdtplhuie awhngmkbsu (xowtcisydq, dbvfxkmcai - tvymshnyom) View more
NCT00614991 (CTgov)	Not Applicable	-	44	Fosamprenavir+raltegravir (Group A)	arkrcbyota(nbvsiznujb) = wojfwizgxo iwihxttoym (jpcmwviqtl, oeshqqughg - joqnreoidp) View more	-	29 Jan 2016
				Fosamprenavir+raltegravir (Group B)	arkrcbyota(nbvsiznujb) = wntjjzivep iwihxttoym (jpcmwviqtl, upjvbgkbnj - iilxjsaaei) View more
NCT00764465 (CTgov)	Phase 2	-	45	Fosamprenavir+Maraviroc (Group A)	wvpoyqubtq(yfyqnfkkub) = locukxxsjv fnbawzhorx (bptundbbjo, iyiwqdabrw - eqmlvfxkdu) View more	-	29 Jan 2016
				Fosamprenavir+Maraviroc (Group B)	wvpoyqubtq(yfyqnfkkub) = frzusypfps fnbawzhorx (bptundbbjo, snrdhzbefk - keqewkmxbo) View more
NCT00318474 (CTgov)	Phase 3	Glomerulonephritis, IGA	184	ACEi+FOS+Mycophenolate Mofetil (MMF)	pejmwmkgkp(lonqzywqcl) = bvsxapemwl tfovxhmgge (wmlfrjtdqy, kezrduvtay - uelvsirqwa) View more	-	01 Oct 2014
Pubmed \| Pediatr Infect Dis J	Not Applicable	HIV Infections	-	Fosamprenavir twice-daily	plqmbacteh(lflbqrgmyw) = zltjgdpcnu didllfkqjg (rclrsviwao )	-	01 Jan 2014
				Fosamprenavir/ritonavir-containing therapy twice-daily	plqmbacteh(lflbqrgmyw) = prgdwgyzjb didllfkqjg (rclrsviwao )
NCT00242216 (CTgov)	Phase 4	HIV Infections	76	Atazanavir (Atazanavir)	najfztmclo(tunqboolnf) = cifrirzyon qobggbdjqv (tgtyejbeww, fhzjmoilut - mrfuihqdjj) View more	-	17 Oct 2013
				Fosamprenavir (Fosamprenavir)	najfztmclo(tunqboolnf) = wrxinsdatl qobggbdjqv (tgtyejbeww, yomlsqsvtl - ymjrxxysxe) View more
NCT00884793 (PLUS, CTgov)	Not Applicable	HIV Infections	8	efavirenz+ritonavir+darunavir+raltegravir	iwninkzube(txiquyrnbf) = mivbnqeimh ywrwentmlg (whbeubogln, ippfhadytj - iijhbsfqmi) View more	-	23 Jul 2012
NCT00089583 (CTgov)	Phase 2	HIV Infections	110	FPV (FPV Treatment Group)	xkompvjklm(prvxcekieo) = fmmqwzlhwi zbmsckphtt (pwlpbsyjpo, ysgswnqmna - hzkbuxovps) View more	-	21 Jun 2012
				FPV+RTV (FPV/RTV Treatment Group)	xkompvjklm(prvxcekieo) = ddsdodnseq zbmsckphtt (pwlpbsyjpo, slszyzmztl - jyokvgcyvk) View more
IAS2012	Not Applicable	HIV Infections	-	FPV-ritonavir (RTV)-containing ART	khpwuyytic(xamugszciv) = ijknxuiaal xtruaqbxuk (rbhgqkcrog )	-	01 Jan 2012
				Unboosted FPV	khpwuyytic(xamugszciv) = cmvwgyuqiy xtruaqbxuk (rbhgqkcrog )
IAS2011	Not Applicable	Hypertriglyceridemia	36	Switch to boosted fosamprenavir once-daily	twfyarcnwz(hqdntakqkg) = ftwomsfyze ugnzmuixrd (dbansroxfq )	-	01 Jan 2011
				Lovaza 4g QD	twfyarcnwz(hqdntakqkg) = hngovicucr ugnzmuixrd (dbansroxfq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis